%PDF-1.4
%
61 0 obj
<>
endobj
58 0 obj
<>
endobj
121 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T16:15:17Z
2024-03-28T09:12:04-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T09:12:04-07:00
application/pdf
Heather
2003-22.dec
uuid:5ac68bee-1dd2-11b2-0a00-3309275d6100
uuid:5ac68bf1-1dd2-11b2-0a00-aa0000000000
endstream
endobj
47 0 obj
<>
endobj
48 0 obj
<>
endobj
62 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
143 0 obj
[147 0 R]
endobj
144 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(placebo in rheumatoid arthritis patients receiving concomitant)Tj
0 -1.25 TD
[(methotrexate: a randomised phase III trial. )54.8 (A)110.8 (TTRACT)-257.3 (Study)]TJ
T*
(Group. Lancet 1999;354:1932-9.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Brandt J, Haibel H, Cornely D, et al. Successful treatment of active)]TJ
1.675 -1.25 Td
(ankylosing spondylitis with the anti-tumour necrosis factor alpha)Tj
T*
[(monoclonal antibody infliximab. )54.8 (Arthritis Rheum 2000;43:1346-52.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Lipsky PE, van der Heijde DMFM, St. Clair EW)91.7 (, Furst DE,)]TJ
1.675 -1.25 Td
(Breedveld FC, Kalden JR. Infliximab and methotrexate in the )Tj
T*
(treatment of RA. N Engl J Med 2000;343:1594-602.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Brandt J, Haibel H, Sieper J, Redding J, Braun J. Infliximab )]TJ
1.675 -1.25 Td
(treatment of severe ankylosing spondylitis: one-year followup.)Tj
T*
(Arthritis Rheum 2001;44:2936-7.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short)]TJ
1.675 -1.25 Td
[(term treatment of severe undif)17.7 (ferentiated spondyloarthropathy with)]TJ
T*
[(the anti-tumor necrosis factor)19.7 (-a monoclonal antibody infliximab. )]TJ
T*
[(J Rheumatol 2002;29:1)36.8 (18-22.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label)]TJ
1.675 -1.25 Td
(study of infliximab treatment for psoriatic arthritis: clinical and)Tj
T*
(magnetic resonance imaging measurements of reduction of )Tj
T*
[(inflammation. )54.8 (Arthritis Rheum 2002;47:506-12.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Phillips K, Husni ME, Karlson E, Coblyn JS. Experience with )]TJ
1.675 -1.25 Td
[(etanercept in an academic medical center: )54.8 (Are the infection rates)]TJ
T*
[(increased? )54.8 (Arthritis Care Res 2002;47:17-21.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Fitzcharles M, Clayton D, M\216nard HA. )17.7 (The use of infliximab in)]TJ
1.675 -1.25 Td
(academic rheumatology practice: an audit of early clinical )Tj
T*
(experience. J Rheumatol 2002;12:2525-30.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Sokka )17.7 (T)74 (, Pincus )17.7 (T)74 (. Contemporary disease modifying antirheumatic)]TJ
2.175 -1.25 Td
(drugs in patients with recent onset rheumatoid arthritis in a US)Tj
T*
(private practice: methotrexate as the anchor drug in 90% and new)Tj
T*
(DMARD in 30% of patients. J Rheumatol 2002;12:2521-4.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Charles PJ, Smeenk RJT)73.9 (, De Jong J, Feldmann M, Maini RN.)]TJ
2.1381 -1.25 Td
[(Assessment of antibodies to double-stranded DNA)-220.2 (induced in)]TJ
T*
(rheumatoid arthritis patients following treatment with infliximab, a)Tj
T*
(monoclonal antibody to tumor necrosis factor alpha: findings in)Tj
T*
[(open-label and randomized placebo-controlled trials. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:2383-90.)Tj
-0.00011 Tc 30.825 43.75 Td
[(12.)-875.1 (Casciola C, Rosen LA, )54.8 (Anhalt G, Rosen )54.8 (A. )54.8 (Autoantigens tar)17.7 (geted)]TJ
2.175 -1.25 Td
(in systemic lupus erythematosus are clustered in two populations of)Tj
T*
(surface structures on apoptotic keratinocytes. J Exp Med)Tj
0 Tc 0 Tw T*
(1994;179:1317-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (ten Hove )17.7 (T)74 (, van Montfrans C, Peppelenbosch MP)110.7 (, van Deventer SJ.)]TJ
2.175 -1.25 Td
[(Infliximab treatment induces apoptosis of lamina propria )17.7 (T)]TJ
T*
[(lymphocytes in Crohn\325)54.8 (s disease. Gut 2002;50:148-9.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (James JA, Harley JB. B-cell epitope spreading in autoimmunity)64.8 (.)]TJ
2.175 -1.25 Td
(Immunol Rev 1998;164:185-200.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Ferraccioli GF)79.7 (, )54.8 (Assaloni R, Di Poi E, Gremese E, De Marchi G,)]TJ
2.175 -1.25 Td
(Fabris M. Rescue of combination therapy failures using infliximab,)Tj
T*
(while maintaining the combination or monotherapy with)Tj
T*
(methotrexate: results of an open trial. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
[(2002;41:1)36.9 (109-12.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Jonsdottir )17.7 (T)74 (, Harju )54.8 (A, van )17.7 (V)128.9 (ollenhoven )54.8 (A, Klareskog L, van)]TJ
2.175 -1.25 Td
[(V)128.9 (ollenhoven R. )17.7 (T)35 (reatment with )17.7 (TNF-antagonists is associated with)]TJ
T*
(an increasing frequency of anticardiolipin antibodies )Tj
T*
[(\(ACLA\) \321 )54.8 (ACLA)-220.2 (positivity predicts worse clinical outcome)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 2002;46 Suppl:S573.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Antivalle M, Marrazza M, Randisi G, et al. Long term treatment of)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis with infliximab: Ef)17.7 (ficacy)64.8 (, side ef)17.7 (fects and)]TJ
T*
[(autoantibody induction [abstract]. )54.8 (Arthritis Rheum 2002;46)]TJ
0 Tw T*
(Suppl:S534.)Tj
0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Bingham S, Barcelos )54.8 (A, Buch M, Lindsay S, Emery P)110.7 (. Induction of)]TJ
2.175 -1.25 Td
(serological lupus in patients on leflunomide and infliximab)Tj
T*
[([abstract]. )54.8 (Arthritis Rheum 2002;46 Suppl:S168.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Favalli EG, Sinigaglia L, )17.7 (V)110.8 (arenna M, )54.8 (Arnoldi C. Drug-induced)]TJ
2.175 -1.25 Td
(lupus following treatment with infliximab in rheumatoid arthritis.)Tj
0 Tc T*
[(Lupus 2002;1)36.9 (1:753-5.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:12)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2562)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
41 0 obj
<>stream
8;Z\7m?3)U#itqk0X#P7c$jUYC)up+DV1!'`X"-"3,PcophP\1*Uh/ZT-%89>XG@H
YKnSN`aB8eC_(7#qeeWB;g9it;H,CAZl)`&q@A8*_-\2R)5WbsFhVCq8_1ckd_9QS9rbV7Uk)\D=Hhub+&;C"EgRN'-nm?<^n1U8V([$0-+\EOCq0\I\2
fj@ci9+7ZsM3&b\)nm,[4eN6mfi3%=Qs*;RmTo0Z5)sf&$nojFmRT"Z!CM%;>2,jD
P>.'1-Oq0'p_JP'F`$V>]U%GZ"EKiT>46!SZeGRdhU@emZ\7#5\//:mTf?Iu7[@AW
QrH!Rh/7j3Thm-O$ACg?n-J$#4C[Bii`#3XgV*R3e=W!p;>kS6$ii!I7`Y~>
endstream
endobj
45 0 obj
[/Indexed/DeviceRGB 255 44 0 R]
endobj
44 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
69 0 obj
<>
endobj
64 0 obj
<>
endobj
108 0 obj
<>
endobj
126 0 obj
<>
endobj
65 0 obj
<>
endobj
99 0 obj
<>stream
HUiTg>!2̨:uaQ$B$"Q@elk;V\3u8ڹ_2K3gg=9Ϲ=}^al0/((dp^*W~0.wM~'̠]0zˍ]c-Zƴ=چRbBc*/&p~|i,aFֵ=鹑齋.%& kqޠ[ޑBn7(?3'&p))췽v&W6dN qlaf\75.8KE\=츴
L6'Ȋxqy4<ۙ=ƻV3nb#0ONh͡f}~Nr;5CQCc$,ބ.rVuv=^ Y='N
p|JZ|Z-O)Q*
{IFO:,nUթZ7VC#~|NHe7|_jfMoxGj2WʫT5
cwo6MdGht.b'8?Q-meliqQBAiBڧ O*)J-JdgɭRI:p`>RyE?
ll ,c2Ga,/HTo_[4\i~CE\0?A'^0gH:@KbMxN$YntCZoP>F9J쒤ˣZY^XZ\VW/F[
hr)[0].PGTo}-ەgTcIL_ ; YӠNTXHXKrvlG"dN³Y!Mo(~ߜV_%z#29[ъF:r%b':;Wt6KMí9Jپz;*)5+yG't{#H!rQwvwOXp֡yu"+%/m@'z88 Yqn~JE(M#~^::Guͷz',r'i6 wz}
^6&/
9W^ʙJTd~:u#d#(rNԙK5}A?F<~Tdq%OyD%φHhT¢r_,_+~N,b/^Y.Vd SW/QXxO9Ћ}5:\oIԥF+!V42[uO>tF=|nI!ǽLܘ?WV`jā5蠳:67i`]H[J
*tW"Jt$Z 2B# + M3(+|sP{kݾ ПQ&qw.]'T8&Ӆ2\evMAcImZ,}'ᴍޛZ2U"jL=nO,f+ZER2
5&9'enWD r@wEk(I,Zܖ* QzU#m[Knrv!ֽJPR[VިhOVyWsːܡG*Vi%6{I۩;!6ț~}DTY"XMhj\g4ڇ(͛R|Uуv)W_H&Ix ,lyT Ǝ#zN]ǡ[;j"XdU-fCH[$@Hxy!QF\JqrԎX}3/X.߿sw>+'r:>=;`fÃo?Z B1
40(`8rЯy6z5Ef5)Bdx-[_М$=١};IhUBJadp;)ptS"!da2AnO&jeyF}